Navigation Links
PDL-1 antibody could help immune system fight off influenza viral infection, study suggests
Date:12/23/2013

An antibody that blocks a component of a key signaling pathway in the respiratory airways could help the immune system rid the body of the influenza virus, a new study suggests. The findings, from a team at The Research Institute at Nationwide Children's Hospital, not only offer a new approach to treating the flu, but also add new information about how the immune system responds to respiratory viral infections.

In this new work, published in the December issue of the Journal of Virology and highlighted in the journal Spotlight section, researchers examined the role a protein called programmed cell death receptor (PD-1) plays in the immune response to influenza virus. PD-1 is known to inhibit the function of T cells, the immune system's first line of defense against intracellular pathogens. While scientists have looked intently at PD-1 activity in chronic viral infections such as hepatitis and HIV, its involvement in acute infections was thought by many to be minor.

Emilio Flao, PhD, principal investigator in the Center for Vaccines and Immunity, disagreed. Several small studies in his lab had raised the possibility that PD-1 and its associated ligand PDL-1 were actually very important to the immune response to acute infection.

The researchers' earlier studies had shown that when PD-1 protein was expressed, but its ligand PDL-1 was not, the protein couldn't bind to T cells to inhibit the immune response. So, for this study, the scientists treated mice infected with influenza virus with an antibody that blocks the activity of PDL-1. Viral levels began to drop within three days of treatment with the PDL-1 antibody, which was administered intranasally. At day five, the viral levels were undetectable.

"The PDL-1 blockade is not directly acting on the virus," Dr. Flao says. "It is acting on the T cells, improving their function so that the immune system can fight the virus."

When they examined the PD-1/PDL-1 response to influenza virus infection in human cell cultures, the scientists discovered that the activity of the protein and its ligand mimicked what they had seen in their mouse models. The findings from this study, coupled with the human tissue observations in the lab, suggest that an aerosolized version of the antibody, administered intranasally, could help the body clear the influenza virus.

"Sometimes it's better to enhance our own defenses and improve how they work rather than trying to target the virus," Dr. Flao says.

Scientists have eyed a PD-1/PDL-1 blockade as a way to treat hepatitis, HIV and other persistent viral infections, but their efforts have so far yielded mixed results in humans. Using the blockade to boost immune response against influenza is a simpler task because the infection is localized to the airways, Dr. Flao hypothesizes.

Dr. Flao and colleagues were also interested in how epithelial cells in the airwaysthe main targets of the influenza virusrespond to the attack and how their reaction might influence the immune system over the course of an infection.

"The original view has been that epithelial cells aren't all that important, but we are trying to change that, says Dr. Flao, who also is an associate professor of pediatrics at The Ohio State University College of Medicine. "The epithelial cells help orchestrate all the subsequent immune response in the body, and I truly believe that what they do at the onset of infection will determine what happens one week or 10 days later, when the immune system is responding at full speed."


'/>"/>

Contact: Mary Ellen Peacock
maryellen.peacock@nationwidechildrens.org
614-355-0495
Nationwide Children's Hospital
Source:Eurekalert

Related medicine news :

1. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
2. Scientists Pinpoint Antibody That May Be Specific to MS Patients
3. NIH scientists map first steps in flu antibody development
4. Elevated Antibody Levels May Predict Rheumatoid Arthritis Risk
5. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
6. Antibody-coated stents: Indication of disadvantages
7. Evolution in the antibody factory
8. Scientists ID Antibody That Might Boost Cancer Therapy
9. Your Autoantibody Profile Might Someday Help Spot Illness
10. Monoclonal antibody appears effective and safe in asthma Phase IIa trial
11. Healthcare Antibody Market Partnering Deals And Agreements Analysis in New Research Report at ReportsnReports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: